Table 1 Pharmacological options for reversing the effect of the direct-acting oral anticoagulants
From: Management of bleeding in patients treated with direct oral anticoagulants
Inhibitor | Conventional dose |
|---|---|
Nonspecific reversal (prohemostatic interventions) | Â |
 Prothrombin complex concentrates | 50 U/kg |
 Activated prothrombin complex concentrates | 50 U/kg |
 Recombinant factor VIIa | 90 μg/kg |
Specific reversal | Â |
 Directed at dabigatran |  |
 Idarucizumab | 5 g |
 Directed at rivaroxaban, apixaban, and edoxaban |  |
 Andexanet-alfa | 600–800 mg |
 Ciraparantag | 100 mg |